title: Postexposure prophylaxis for rabies with antiserum and intradermal vaccination.
abstract: The Thai Red Cross intradermal postexposure rabies treatment schedule was prospectively assessed in 100 Thai patients severely bitten by proven rabid animals. It consists of 0.1 ml of purified Vero cell rabies vaccine containing more than 2.5 IU of rabies antigen per 0.5 ml of reconstituted vaccine given intradermally at two sites on days 0, 3, and 7, followed by one 0.1 ml injection on days 30 and 90. The commercial vaccine used had an antigen content of 3.17 IU per 0.5 ml ampoule. Purified equine or human rabies immuno-globulin was also given on day 0 to patients with severe exposures. As much of the immunoglobulin as possible was infiltrated around the wounds. All patients were followed for 1 year post exposure. There were no deaths; the efficacy of the regimen was 100%. Antibody titre determination in a randomly selected subgroup showed seroconversion in all 10 patients.
authors.affiliation: Queen Saovabha Memorial Institute, Thai Red Cross Society, Bangkok, Thailand.
authors.forename: S
authors.initials: S
authors.lastname: Chutivongse
authors.forename: H
authors.initials: H
authors.lastname: Wilde
authors.forename: C
authors.initials: C
authors.lastname: Supich
authors.forename: G M
authors.initials: GM
authors.lastname: Baer
authors.forename: D B
authors.initials: DB
authors.lastname: Fishbein
mesh_terms: D000293:Adolescent; D000328:Adult; D000917:Antibody Formation; D001733:Bites and Stings / Q000150:complications*; D002648:Child; D002675:Child, Preschool; D003365:Costs and Cost Analysis; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007111:Immunity, Cellular; D007115:Immunization Schedule; D007223:Infant; D007271:Injections, Intradermal; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011818:Rabies / Q000276:immunology / Q000401:mortality / Q000517:prevention & control*; D011819:Rabies Vaccines / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D012494:Sampling Studies; D013785:Thailand; D013997:Time Factors
chemical_list: D011819:Rabies Vaccines